Handforth A - Search Results

1

Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications.

Martin FC, Thu Le A, Handforth A. Martin FC, et al. Among authors: handforth a. Mov Disord. 2005 Mar;20(3):298-305. doi: 10.1002/mds.20331. Mov Disord. 2005. PMID: 15580562

2

Suppression of harmaline-induced tremor in rats by vagus nerve stimulation.

Handforth A, Krahl SE. Handforth A, et al. Mov Disord. 2001 Jan;16(1):84-8. doi: 10.1002/1531-8257(200101)16:1<84::aid-mds1010>3.0.co;2-s. Mov Disord. 2001. PMID: 11215598

3

Vagus nerve stimulation inhibits harmaline-induced tremor.

Krahl SE, Martin FC, Handforth A. Krahl SE, et al. Among authors: handforth a. Brain Res. 2004 Jun 11;1011(1):135-8. doi: 10.1016/j.brainres.2004.03.021. Brain Res. 2004. PMID: 15140653

4

Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor.

Handforth A, Martin FC. Handforth A, et al. Mov Disord. 2004 Oct;19(10):1215-21. doi: 10.1002/mds.20147. Mov Disord. 2004. PMID: 15390011 Clinical Trial.

5

Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor.

Martin FC, Handforth A. Martin FC, et al. Among authors: handforth a. Mov Disord. 2006 Oct;21(10):1641-9. doi: 10.1002/mds.20940. Mov Disord. 2006. PMID: 16773639

6

Zonisamide for essential tremor: an evaluator-blinded study.

Handforth A, Martin FC, Kang GA, Vanek Z. Handforth A, et al. Mov Disord. 2009 Feb 15;24(3):437-40. doi: 10.1002/mds.22418. Mov Disord. 2009. PMID: 19117357

7

T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.

Handforth A, Homanics GE, Covey DF, Krishnan K, Lee JY, Sakimura K, Martin FC, Quesada A. Handforth A, et al. Neuropharmacology. 2010 Nov;59(6):380-7. doi: 10.1016/j.neuropharm.2010.05.012. Epub 2010 Jun 12. Neuropharmacology. 2010. PMID: 20547167 Free PMC article.

8

A pilot efficacy and tolerability trial of memantine for essential tremor.

Handforth A, Bordelon Y, Frucht SJ, Quesada A. Handforth A, et al. Clin Neuropharmacol. 2010 Sep-Oct;33(5):223-6. doi: 10.1097/WNF.0b013e3181ebd109. Clin Neuropharmacol. 2010. PMID: 20838216 Clinical Trial.

9

Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor.

Quesada A, Bui PH, Homanics GE, Hankinson O, Handforth A. Quesada A, et al. Among authors: handforth a. Eur J Pharmacol. 2011 May 20;659(1):30-6. doi: 10.1016/j.ejphar.2011.01.004. Epub 2011 Jan 21. Eur J Pharmacol. 2011. PMID: 21256842 Free PMC article.

10

Octanoic acid suppresses harmaline-induced tremor in mouse model of essential tremor.

Nahab FB, Handforth A, Brown T, Shin C, Quesada A, Dong C, Haubenberger D, Hallett M. Nahab FB, et al. Among authors: handforth a. Neurotherapeutics. 2012 Jul;9(3):635-8. doi: 10.1007/s13311-012-0121-1. Neurotherapeutics. 2012. PMID: 22454323 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters